Is Asciminib on the market?

Asciminib (Asciminib) was approved for marketing by the U.S. Food and Drug Administration (FDA) on October 29, 2021, and is currently sold under the trade name of Scemblix. Aceminib is a tyrosine kinase inhibitor (TKI) that can be used to treat chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML),It has also shown benefit in Ph+CML harboring the T315I mutation, which creates mutant BCR-ABL1, which is often therapeutically resistant compared to wild-type BCR-ABL2.

More specifically, aceminib is an inhibitor of the kinase activity of the BCR-ABL1 fusion protein ABL1, which is a driver of chronic myelogenous leukemia proliferation in the majority of patients with the disease. On June 23, 2022, the European Medicines Agency (EMA) recommended approval of the marketing authorization of the drug aceminib, which is intended for the treatment of adults with the chronic phase of Philadelphia chromosome-positive chronic myelogenous leukemia who have previously been treated with two or more tyrosine kinase inhibitors. The applicant for this drug is Novartis Europe Pharmaceuticals Ltd. Acemini was approved for medical use in the EU in August 2022.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in medical insurance. The original drug of Asiminib currently sold overseas is very expensive. Generic drugs of Asiminil are also produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rate effects), and the price is relatively cheap. For more drug information and specific prices, please consult Yaode’s medical consultant.